ID

35465

Descripción

Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02248805

Link

https://clinicaltrials.gov/show/NCT02248805

Palabras clave

Versiones (1)
  1. 5/3/19 5/3/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

5 de marzo de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Colorectal Carcinoma NCT02248805

Inglés

Eligibility Colorectal Carcinoma NCT02248805

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
for the dose escalation cohorts, histologically-proven metastatic colorectal adenocarcinoma that is refractory to 2 prior standard treatment regimens or standard treatment was declined.
Descripción

Dose Escalation Cohort | Adenocarcinoma of large intestine metastatic | Unresponsive to Standard therapy Quantity | Standard therapy Rejected

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3816728
UMLS CUI [1,2]
C0599755
UMLS CUI [2,1]
C1319315
UMLS CUI [2,2]
C1522484
UMLS CUI [3,1]
C0205269
UMLS CUI [3,2]
C2936643
UMLS CUI [3,3]
C1265611
UMLS CUI [4,1]
C2936643
UMLS CUI [4,2]
C1548437
for the dose expansion cohorts, histologically-proven metastatic colorectal adenocarcinoma that is refractory to 1 prior standard treatment regimen or standard therapy was declined.
Descripción

Dose Expansion Cohort | Adenocarcinoma of large intestine metastatic | Unresponsive to Standard therapy Quantity | Standard therapy Rejected

Tipo de datos

boolean

Alias
UMLS CUI [1]
C4521283
UMLS CUI [2,1]
C1319315
UMLS CUI [2,2]
C1522484
UMLS CUI [3,1]
C0205269
UMLS CUI [3,2]
C2936643
UMLS CUI [3,3]
C1265611
UMLS CUI [4,1]
C2936643
UMLS CUI [4,2]
C1548437
eastern cooperative oncology group (ecog) performance status of 0 or 1
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
life expectancy of at least 12 weeks
Descripción

Life Expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
measurable disease
Descripción

Measurable Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1513041
intolerance to at least 2 prior standard therapy regimens
Descripción

Intolerance Standard therapy Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0231199
UMLS CUI [1,2]
C2936643
UMLS CUI [1,3]
C1265611
acceptable laboratory parameters
Descripción

Laboratory Results Acceptable

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1254595
UMLS CUI [1,2]
C1879533
adult (≥18 years old)
Descripción

Adult | Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
known brain metastasis
Descripción

Metastatic malignant neoplasm to brain

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0220650
any prior history of or suspected current autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior grave's disease)
Descripción

Autoimmune Diseases | Autoimmune Diseases Suspected | Exception Vitiligo | Exception Childhood atopic dermatitis resolved | Exception Graves Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0004364
UMLS CUI [2,1]
C0004364
UMLS CUI [2,2]
C0750491
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0042900
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1276071
UMLS CUI [4,3]
C1514893
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0018213
prior history of allogeneic bone marrow, stem-cell, or solid organ transplantation
Descripción

Allogeneic bone marrow transplantation | Allogeneic Stem Cell Transplantation | Solid organ transplant Allogeneic

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0149615
UMLS CUI [2]
C2242529
UMLS CUI [3,1]
C0730400
UMLS CUI [3,2]
C1515895
prior treatment with checkpoint inhibitors and other immunotherapy treatments, including anti-lag-3, anti-pd-1, anti-pd-l1 or anti-ctla-4 antibodies, if less than 5 half lives before study drug administration
Descripción

Other Coding | Immunotherapy | Anti-LAG-3 Monoclonal Antibody | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | Anti-CTLA-4 Monoclonal Antibody

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3846158
UMLS CUI [2]
C0021083
UMLS CUI [3]
C4525145
UMLS CUI [4]
C4289970
UMLS CUI [5]
C4289971
UMLS CUI [6]
C4289973
prior history of grade 3 or greater drug-related diarrhea/colitis during treatment with checkpoint inhibitors or other immunotherapy treatments.
Descripción

Diarrhea due to drug Grade | Drug-induced colitis Grade | Other Coding | Immunotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1996989
UMLS CUI [1,2]
C0441800
UMLS CUI [2,1]
C0341336
UMLS CUI [2,2]
C0441800
UMLS CUI [3]
C3846158
UMLS CUI [4]
C0021083
treatment with any local or systemic anti-neoplastic therapy or any other investigational agent in the 4 weeks prior to study drug administration
Descripción

Cancer treatment Local | Cancer treatment Systemic | Investigational New Drugs

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205276
UMLS CUI [2,1]
C0920425
UMLS CUI [2,2]
C0205373
UMLS CUI [3]
C0013230
require, at the time of study entry, treatment with steroids > 10 mg/day of oral prednisone (or equivalent), except topical use, steroid inhaler, nasal spray or ophthalmic solution
Descripción

Steroids | Prednisone Oral Product U/day | Equivalent | Exception Topical steroids | Exception Inhaled steroids use | Exception Steroids Nasal Spray | Exception Steroids Ophthalmic Solution

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0038317
UMLS CUI [2,1]
C3216040
UMLS CUI [2,2]
C0456683
UMLS CUI [3]
C0205163
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C2064827
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0586793
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0038317
UMLS CUI [6,3]
C0461725
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0038317
UMLS CUI [7,3]
C0029083
history of clinically significant cardiovascular disease, gastrointestinal disorder, or significant pulmonary compromise.
Descripción

Cardiovascular Disease | Gastrointestinal Diseases | Pulmonary function impairment

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C0017178
UMLS CUI [3]
C0858943
second primary malignancy that has not been in remission for greater than 3 years, with the exception of non-melanoma skin cancer, cervical carcinoma in situ,or squamous intraepithelial lesion on pap smear, localized prostate cancer (gleason score <6), or resected melanoma in situ.
Descripción

Second Primary Cancer | Remission Absent | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix | Exception Squamous intraepithelial lesion Pap smear | Exception Prostate carcinoma Localized Gleason score | Exception Melanoma in situ Resected

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0751623
UMLS CUI [2,1]
C0687702
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0699893
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0851140
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0333873
UMLS CUI [5,3]
C0079104
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0600139
UMLS CUI [6,3]
C0392752
UMLS CUI [6,4]
C3203027
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0854696
UMLS CUI [7,3]
C1521996
Volver a la parte superior de la página

Similar models

Eligibility Colorectal Carcinoma NCT02248805

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Dose Escalation Cohort | Adenocarcinoma of large intestine metastatic | Unresponsive to Standard therapy Quantity | Standard therapy Rejected
Item
for the dose escalation cohorts, histologically-proven metastatic colorectal adenocarcinoma that is refractory to 2 prior standard treatment regimens or standard treatment was declined.
boolean
C3816728 (UMLS CUI [1,1])
C0599755 (UMLS CUI [1,2])
C1319315 (UMLS CUI [2,1])
C1522484 (UMLS CUI [2,2])
C0205269 (UMLS CUI [3,1])
C2936643 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C2936643 (UMLS CUI [4,1])
C1548437 (UMLS CUI [4,2])
Dose Expansion Cohort | Adenocarcinoma of large intestine metastatic | Unresponsive to Standard therapy Quantity | Standard therapy Rejected
Item
for the dose expansion cohorts, histologically-proven metastatic colorectal adenocarcinoma that is refractory to 1 prior standard treatment regimen or standard therapy was declined.
boolean
C4521283 (UMLS CUI [1])
C1319315 (UMLS CUI [2,1])
C1522484 (UMLS CUI [2,2])
C0205269 (UMLS CUI [3,1])
C2936643 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C2936643 (UMLS CUI [4,1])
C1548437 (UMLS CUI [4,2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of at least 12 weeks
boolean
C0023671 (UMLS CUI [1])
Measurable Disease
Item
measurable disease
boolean
C1513041 (UMLS CUI [1])
Intolerance Standard therapy Quantity
Item
intolerance to at least 2 prior standard therapy regimens
boolean
C0231199 (UMLS CUI [1,1])
C2936643 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Laboratory Results Acceptable
Item
acceptable laboratory parameters
boolean
C1254595 (UMLS CUI [1,1])
C1879533 (UMLS CUI [1,2])
Adult | Age
Item
adult (≥18 years old)
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Metastatic malignant neoplasm to brain
Item
known brain metastasis
boolean
C0220650 (UMLS CUI [1])
Autoimmune Diseases | Autoimmune Diseases Suspected | Exception Vitiligo | Exception Childhood atopic dermatitis resolved | Exception Graves Disease
Item
any prior history of or suspected current autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior grave's disease)
boolean
C0004364 (UMLS CUI [1])
C0004364 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0042900 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C1276071 (UMLS CUI [4,2])
C1514893 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0018213 (UMLS CUI [5,2])
Allogeneic bone marrow transplantation | Allogeneic Stem Cell Transplantation | Solid organ transplant Allogeneic
Item
prior history of allogeneic bone marrow, stem-cell, or solid organ transplantation
boolean
C0149615 (UMLS CUI [1])
C2242529 (UMLS CUI [2])
C0730400 (UMLS CUI [3,1])
C1515895 (UMLS CUI [3,2])
Other Coding | Immunotherapy | Anti-LAG-3 Monoclonal Antibody | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | Anti-CTLA-4 Monoclonal Antibody
Item
prior treatment with checkpoint inhibitors and other immunotherapy treatments, including anti-lag-3, anti-pd-1, anti-pd-l1 or anti-ctla-4 antibodies, if less than 5 half lives before study drug administration
boolean
C3846158 (UMLS CUI [1])
C0021083 (UMLS CUI [2])
C4525145 (UMLS CUI [3])
C4289970 (UMLS CUI [4])
C4289971 (UMLS CUI [5])
C4289973 (UMLS CUI [6])
Diarrhea due to drug Grade | Drug-induced colitis Grade | Other Coding | Immunotherapy
Item
prior history of grade 3 or greater drug-related diarrhea/colitis during treatment with checkpoint inhibitors or other immunotherapy treatments.
boolean
C1996989 (UMLS CUI [1,1])
C0441800 (UMLS CUI [1,2])
C0341336 (UMLS CUI [2,1])
C0441800 (UMLS CUI [2,2])
C3846158 (UMLS CUI [3])
C0021083 (UMLS CUI [4])
Cancer treatment Local | Cancer treatment Systemic | Investigational New Drugs
Item
treatment with any local or systemic anti-neoplastic therapy or any other investigational agent in the 4 weeks prior to study drug administration
boolean
C0920425 (UMLS CUI [1,1])
C0205276 (UMLS CUI [1,2])
C0920425 (UMLS CUI [2,1])
C0205373 (UMLS CUI [2,2])
C0013230 (UMLS CUI [3])
Steroids | Prednisone Oral Product U/day | Equivalent | Exception Topical steroids | Exception Inhaled steroids use | Exception Steroids Nasal Spray | Exception Steroids Ophthalmic Solution
Item
require, at the time of study entry, treatment with steroids > 10 mg/day of oral prednisone (or equivalent), except topical use, steroid inhaler, nasal spray or ophthalmic solution
boolean
C0038317 (UMLS CUI [1])
C3216040 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
C0205163 (UMLS CUI [3])
C1705847 (UMLS CUI [4,1])
C2064827 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0586793 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0038317 (UMLS CUI [6,2])
C0461725 (UMLS CUI [6,3])
C1705847 (UMLS CUI [7,1])
C0038317 (UMLS CUI [7,2])
C0029083 (UMLS CUI [7,3])
Cardiovascular Disease | Gastrointestinal Diseases | Pulmonary function impairment
Item
history of clinically significant cardiovascular disease, gastrointestinal disorder, or significant pulmonary compromise.
boolean
C0007222 (UMLS CUI [1])
C0017178 (UMLS CUI [2])
C0858943 (UMLS CUI [3])
Second Primary Cancer | Remission Absent | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix | Exception Squamous intraepithelial lesion Pap smear | Exception Prostate carcinoma Localized Gleason score | Exception Melanoma in situ Resected
Item
second primary malignancy that has not been in remission for greater than 3 years, with the exception of non-melanoma skin cancer, cervical carcinoma in situ,or squamous intraepithelial lesion on pap smear, localized prostate cancer (gleason score <6), or resected melanoma in situ.
boolean
C0751623 (UMLS CUI [1])
C0687702 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0699893 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0333873 (UMLS CUI [5,2])
C0079104 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C0600139 (UMLS CUI [6,2])
C0392752 (UMLS CUI [6,3])
C3203027 (UMLS CUI [6,4])
C1705847 (UMLS CUI [7,1])
C0854696 (UMLS CUI [7,2])
C1521996 (UMLS CUI [7,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial